HIV

Contributor: Every Day Is HIV Awareness Day—The Importance of Motivating People to Get Tested for HIV

September 27th 2022, 1:10pm

Dr David Koren Discusses Barriers to Implementing Long-Acting Injectables for HIV

September 22nd 2022, 8:17pm

David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, explains the barriers both patients and providers face in implementing long-acting injectables for HIV.

What We’re Reading: AMA Joins Class-Action Lawsuit; Monkeypox Brain Inflammation; San Francisco HIV Cases

September 14th 2022, 2:19pm

The American Medical Association (AMA) and 2 state medical societies joined a class-action lawsuit against Cigna for underpaying claims filed by providers; 2 cases of monkeypox have led to brain inflammation; for the first time, gay and bisexual men make up less than half of new HIV cases in San Francisco.

Dr Anchalee Avihingsanon: We Can Learn About Curing Hepatitis B From Investigating HIV

September 10th 2022, 4:45pm

Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial, currently evaluating the responses of treatment-naïve persons living with comorbid HIV/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.

Survey Reveals Injectable HIV PrEP Preferences of Young Men Who Have Sex With Men

September 7th 2022, 5:39pm

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and delivery method.

Dr Anchalee Avihingsanon: We Need More Study on Hep B Endurance in PLWH

September 3rd 2022, 3:39pm

The ALLIANCE trial is investigating the responses of treatment-naïve persons living with comorbid HIV (PLWH)/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.

Tailored Video Doctor Intervention May Benefit Certain PLWH

September 1st 2022, 5:41pm

A highly tailored video doctor intervention was shown to help men living with HIV achieve viral suppression, and younger and older patients achieve HIV care retention.

Immune Responses to ART Vary by Regimen Among Individuals With Advanced HIV

August 30th 2022, 7:40pm

People with advanced HIV initiating bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were more likely to reach CD4 cell count levels of 200 cells/mcL or higher compared with those initiating other antiretroviral therapy (ART) regimens.

Confidentiality Protections for Minors Seeking STI, HIV Services Vary Across US

August 25th 2022, 8:02pm

Patient confidentiality is a major reason why minors do not seek out prevention, testing, and treatment services for sexually transmitted infections (STIs) and HIV.

Black, Latinx Transgender Women Cite Multiple Motivations for PrEP Use

August 22nd 2022, 9:10pm

Black and Latinx transgender women expressed high levels of HIV risk perception at the individual and community level, both of which played major roles in their decision to start and continue pre-exposure prophylaxis (PrEP).